NASDAQ:CPRX - Catalyst Pharmaceuticals, Inc.
$2.91
 $0.06
+2.11%
4:20PM EDT
2019-02-22
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CPRX     avg for
industry   		  avg for
sector  
42 stocks weight:  10. 13   0. 00   0. 00  
42 stocks rank:  3. 90 K 2. 00 K 1. 08 K
# analyst opinions:  6. 00   14. 68   14. 18  
quick ratio:  17. 78   5. 17   1. 75  
current ratio:  18. 01   5. 48   2. 10  
target price low:  $ 2. 86   $ 90. 05   $ 118. 16  
target price avg:  $ 6. 50   $ 115. 98   $ 142. 03  
target price high:  $ 8. 17   $ 141. 44   $ 162. 86  
1-yr high:  $ 3. 84   $ 124. 28   $ 143. 16  
last close:  $ 2. 91   $ 102. 75   $ 129. 63  
50-day avg:  $ 2. 43   $ 98. 90   $ 122. 76  
200-day avg:  $ 2. 97   $ 100. 04   $ 123. 17  
1-yr low:  $ 1. 92   $ 78. 22   $ 100. 14  
volume:  974. 21 K 2. 36 M 4. 94 M
50-day avg volume:  1. 22 M 3. 14 M 4. 85 M
200-day avg volume:  1. 14 M 3. 12 M 4. 26 M
1-day return:  2. 11 % 1. 74 % 0. 96 %
this week return:  5. 05 % -0. 72 % -0. 25 %
12-wk return:  14. 57 % 1. 23 % -0. 75 %
52-wk return:  -12. 38 % -2. 03 % 16. 23 %
enterprise value (EV):  $ 222. 92 M $ 54. 82 B $ 107. 48 B
market cap:  $ 298. 98 M $ 47. 12 B $ 97. 54 B
EBITDA:  $ -25. 93 M $ 4. 72 B $ 7. 18 B
enterprise multiple (EV/EBITDA):  -8. 60   9. 03   16. 84  
total debt:  $ 0. 00   $ 13. 41 B $ 16. 70 B
net income (common):  $ -24. 89 M $ 2. 34 B $ 3. 61 B
shares outstanding:  102. 74 M 594. 48 M 1. 22 B
shares:  79. 84 M 592. 96 M 1. 15 B
shares short:  7. 01 M 10. 54 M 11. 92 M
shares short prior month:  4. 42 M 11. 90 M 11. 87 M
short ratio:  7. 61   4. 86   3. 18  
short % of float:  7. 32 % 6. 23 % 2. 78 %
total cash/share:  $ 0. 60   $ 11. 99   $ 10. 04  
total cash:  $ 61. 66 M $ 7. 30 B $ 7. 05 B
free cash flow:  $ -12. 80 M $ 176. 15 M $ 2. 43 B
operating cash flow:  $ -21. 42 M $ 277. 94 M $ 3. 06 B
book value:  $ 0. 62   $ 15. 06   $ 28. 80  
price/book:  4. 66   -0. 58   -2. 51  
operating margins:  0. 00 % -466. 96 % -635. 17 %
EBITDA margins:  0. 00 % 13. 54 % 22. 51 %
profit margins:  0. 00 % 6. 67 % 10. 02 %
gross margins:  0. 00 % 48. 21 % 54. 28 %
1-yr max volatility:  16. 37 % --- ---
1-yr mean volatility:  0. 04 % 0. 01 % 0. 07 %
1-yr EPS:  -0. 25   3. 08   4. 11  
forward EPS:  -0. 15   4. 75   7. 18  
P/E:  -11. 69   15. 54   29. 27  
forward P/E:  -19. 00   -20. 90   3. 33  
PE/G:  1. 87   1. 33   6. 07  
growth:  -6. 23 % 755. 42 % 114. 65 %
earnings high:  $ -0. 08   $ 1. 33   $ 1. 68  
earnings avg:  $ -0. 12   $ 0. 97   $ 1. 54  
earnings low:  $ -0. 15   $ 0. 70   $ 1. 41  
revenue high:  $ -0. 00   $ 2. 81 B $ 11. 37 B
revenue avg:  $ -0. 00   $ 2. 70 B $ 11. 06 B
revenue low:  $ -0. 00   $ 2. 61 B $ 10. 84 B
return on assets:  -31. 71 % -3. 63 % 3. 73 %
return on equity:  -51. 96 % 102. 34 % 26. 90 %
beta (1yr vs S&P500):  1. 10   1. 22   0. 94  
sharpe (1yr):  0. 17   0. 14   1. 05  
held % insiders:  6. 89 % 6. 40 % 3. 16 %
held % institutions:  48. 15 % 79. 62 % 70. 81 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-22 : CPRX
.    + 1.457 =         1.457 :: INITIAL WEIGHT
.  + 130.846 =       132.303 :: inverse volume-to-price addition
.   + 289.05 =       421.353 :: spline projection addition
.  - 141.157 =       280.196 :: poor performance penalty
.    x 0.953 =       267.002 :: one-year gains+dividend factor
.    x 6.798 =      1815.135 :: 13 weeks' performance factor
.    x 1.478 =      2682.667 :: industry recommendation factor
.    x 0.997 =       2674.16 :: return on assets factor
.    x 0.995 =      2660.264 :: return on equity factor
.    x 3.452 =      9184.183 :: current ratio factor
.    x 1.029 =      9453.904 :: quick ratio factor
.    x 1.064 =     10055.888 :: short ratio factor
.    x 2.047 =     20580.728 :: price-to-book factor
.    x 1.156 =     23785.492 :: 5-day avg > 50-day avg
.    x 1.947 =     46317.747 :: P/E weight
.    x 0.855 =     39584.553 :: PE/G factor
.    x 1.756 =     69514.497 :: beta factor
.    x 0.167 =     11630.858 :: sharpe factor
.    x 0.988 =     11485.885 :: target low factor
.     x 1.37 =     15738.381 :: target mean factor
.    x 1.134 =     17854.336 :: target high factor
.    x 1.012 =     18074.158 :: industry 12-weeks return
.    x 0.994 =     17973.613 :: "drift" penalty 4 days ago
.    x 0.986 =     17729.709 :: overall "drift" factor
.    x 0.836 =     14827.056 :: largest single-day jump factor
.     x 0.07 =      1039.037 :: low price factor
.      x 1.0 =      1038.929 :: factor hist industry gain for week 07
.   cubeRoot =        10.128 :: reduced for readability
.                     10.128 :: FINAL WEIGHT for NASDAQ:CPRX

 

News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org